Zhitong Finance App News, Hebang Biotech (603077.SH) disclosed its 2023 annual report. The company achieved revenue of 8.824 billion yuan in 2023, a year-on-year decrease of 32.33%; net profit to mother was 1,283 billion yuan, a year-on-year decrease of 66.29%; after deducting non-net profit of 1,235 billion yuan, a year-on-year decrease of 67.07%; and basic earnings per share were 0.1,474 yuan.

The company's current operating income, net profit attributable to shareholders of listed companies, and basic earnings per share all declined sharply compared to the same period last year, mainly due to weak market demand for the company's main products, diglyphosate and glyphosate, and falling prices.